Specialty Pharma Journal Specialty, Precision & Technology
SALT LAKE CITY, Dec. 07, 2018 (GLOBE NEWSWIRE) — Myriad Genetics, Inc. (NASDAQ: MYGN), a global leader in personalized medicine, today announced that academic researchers from the Technical University of Munich (TUM) presented the first prospective outcomes data on EndoPredict® at the San Antonio Breast Cancer Symposium in San Antonio, Texas. …
Tag Archives: precision medicine
December, 2018
November, 2018
-
1 November
23andMe Granted the First and Only FDA Authorization For Direct-to-Consumer Pharmacogenetic Reports
Mountain View, California – October 31, 2018 – In another first, the U.S. Food and Drug Administration (FDA) granted 23andMe de novo authorization to offer reports on pharmacogenetics, indicating how customers’ genetics may influence the way they metabolize certain medications. This is the first authorization of a direct-to-consumer report on pharmacogenetics, and came …
August, 2018
-
30 August
Vertex and Genomics plc Collaborate to Use Human Genetics and Data Science to Advance Discovery of Precision Medicines
BOSTON & OXFORD, United Kingdom–(BUSINESS WIRE)–Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and Genomics plc today announced a three-year collaboration, extendable to five years, to use human genetics and machine learning to improve discovery of targets for precision medicines, and to advance understanding of the clinical impact of human genetic variation and …
-
9 August
Premier Partners with Progknowse to Develop Precision Medicine Analytics
CHARLOTTE, N.C. & TYSONS, Va.–(BUSINESS WIRE)–Premier Inc. (NASDAQ: PINC), a healthcare improvement company, is partnering with Progknowse, Inc. to develop a clinical and genomic data set for use within the PremierConnect® performance improvement platform to develop new predictive analytics capabilities that support precision medicine and personalized care delivery. Premier and Progknowse …
July, 2018
-
11 July
Otsuka to Expand its Pipeline of Antibody-Based Therapies through its $430 Million Acquisition of Visterra
TOKYO & WALTHAM, Mass.–(BUSINESS WIRE)–Otsuka Pharmaceutical Co., Ltd. (Otsuka) and Visterra, Inc. (Visterra) announce that they have entered into a definitive merger agreement pursuant to which Otsuka will acquire Visterra for approximately USD 430 million in an all-cash transaction. The Otsuka and Visterra boards of directors have approved the transaction. …
-
5 July
Discovery of New Biomarker Could Provide Personalized Treatment Options for Bladder Cancer
A potential new target for treatment has been identified in an aggressive form of bladder cancer, Mount Sinai researchers report. The cancer, called p53-like bladder cancer, is named after an active gene signature it is associated with. It is often particularly aggressive, though individual prognoses can vary quite a bit. …
May, 2018
-
11 May
Scientists Identify Cause of Resistance to Breakthrough Breast and Ovarian Cancer Drug
Scientists have identified a mutation that gives cancer cells resistance to the breakthrough cancer treatment olaparib and other PARP inhibitors. The study findings could help predict which patients will develop resistance to PARP inhibitors and allow doctors to alter treatment at the earliest possible opportunity. A team at The Institute …
-
3 May
Foundation Medicine Launches Gene Expression Profiling Program to Identify Known and Novel Biomarkers in Advanced Cancer
CAMBRIDGE, Mass.–(BUSINESS WIRE)–Foundation Medicine, Inc. (NASDAQ:FMI) today announced a comprehensive gene expression profiling (GEP) program to support precision oncology clinical research and development. This initiative, which provides a natural complement to Foundation Medicine’s comprehensive genomic profiling (CGP) suite of molecular information tests, further enhances support for the Company’s biopharma partners in …
January, 2018
-
18 January
MDxHealth Develops Blood Test to Guide Precision-Treatment of Castration-Resistant Prostate Cancer Patients
HERSTAL, BELGIUM and IRVINE, CA, January 18, 2018 – MDxHealth SA (“MDxHealth, or the “Company”), (Euronext: Brussels MDXH.BR), an international healthcare company, developing and offering molecular diagnostic tests to personalize the diagnosis and treatment of urologic cancer, today announced promising research results with a new liquid biopsy test in development. Data from this …
December, 2017
-
27 December
Innovation Pharmaceuticals Obtains Evidence of Molecular Pathways Modulation in Tumors from Patients in Kevetrin Mid-Stage Ovarian Cancer Trial
BEVERLY, Mass., Dec. 27, 2017 (GLOBE NEWSWIRE) — Innovation Pharmaceuticals Inc., (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, is pleased to announce highly encouraging preliminary data from the first patients treated in the Company’s Phase 2a clinical trial (see NCT03042702) of Kevetrin for ovarian cancer. Modulation of the p53 …